NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

Source :: Plus Company Updates. August 20, 2021
Publication Year :: 2021
Abstract: RADNOR: NRx Pharmaceuticals has issued the following news release: NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI (aviptadil) which is being [...]

Subjects :: United States. National Institutes of Health -- Safety and security measures
Medical research -- Reports -- Safety and security measures
Medicine, Experimental -- Reports -- Safety and security measures
General interest
News, opinion and commentary

Tools